Prophylaxis Regimens Reduce Neratinib-Associated Diarrhea in HER2+ Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Saturday, May 04, 2019
breast cancer
A loperamide prophylactic regimen with or without the addition of either budesonide or colestipol in patients with HER2-positive early breast cancer who received treatment with neratinib (Nerlynx) led to a significant reduction in incidence and severity of diarrhea, according to updated safety results of the phase II CONTROL trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication